Last reviewed · How we verify
NCT07534943
Effectiveness of Oleanolic Acid as Intracanal Medicament on Infectious/Inflammatory Contents in Teeth With Apical Periodontitis
NA trial testing Root canal treatment in Intracanal Medicaments in 36 participants. Participants enrolled and being followed up; not accepting new ones.
1 June 2026
Quick facts
| Lead sponsor | Mansoura University |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 1 March 2026 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Root canal treatment
Conditions studied
- Intracanal Medicaments — all drugs for Intracanal Medicaments →
- Inflammatory Cytokines — all drugs for Inflammatory Cytokines →
- Endodotic Microbiota — all drugs for Endodotic Microbiota →
Sponsor
Mansoura University
Who can join
Adults 20 to 60, any sex, with Intracanal Medicaments or Inflammatory Cytokines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to investigate "clinically" the effectiveness of Oleanolic acid based intracanal medicament compared to the commonly used intracanal medicaments (Calcium hydroxide and Ledermix) on the levels of bacteria in root canals and inflammatory cytokines in the periradicular tissues of teeth with apical periodontitis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07534943
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Root canal treatment
Trials testing the same drug.
- NCT07375576 — Outcomes of Pulpotomy and Root Canal Treatment in Teeth With Symptomatic Irreversible Pulpitis · NA · recruiting
- NCT07163975 — Complete Pulpotomy and Root Canal Treatment Patients With Irreversible Pulpitis With Type 2 Diabetes Mellitus · NA · recruiting
- NCT06671743 — Premedication on Post-endodontic Pain · Phase 3 · recruiting
- NCT06468085 — Evaluation of Pulpotomy Using Two Different Agents in Mature Anterior Teeth With Pulpitis · NA · not yet recruiting
- NCT06086249 — Clinical and Radiographic Success of Regeneration Using Injectable Platelet Rich Fibrin · NA · unknown
Other Mansoura University trials
Trials by the same sponsor.
- NCT05785377 — Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
- NCT07509567 — Conventional Palatal Crib Versus Bonded Spurs for Anterior Open Bite Treatment · NA · not yet recruiting
- NCT07393178 — Efficacy & Safety of High Power vs. Low Power Holmium Laser in Mini-PCNL for Large Renal Stones · NA · not yet recruiting
- NCT07248605 — Emergency Obstetric Care Protocol · NA · not yet recruiting
- NCT07436182 — Mitochondrial Redox Modulation in Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Trial Comparing Imeglimin vs. · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07534943 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mansoura University
- Last refreshed: 16 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07534943.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing